NCT05162443 is a clinical trial of adagrasib (MRTX849) in Advanced Cancer, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT05162443?

NCT05162443 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT05162443?

Interventions in NCT05162443: adagrasib (MRTX849).

What condition does NCT05162443 study?

NCT05162443 studies Advanced Cancer, Metastatic Cancer, Malignant Neoplasm.

Is NCT05162443 still recruiting?

NCT05162443 is currently approved for marketing. Last updated 26 August 2025.

Last reviewed 2025-08-26 · How we verify

NCT05162443

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

APPROVED FOR MARKETING Last updated 26 August 2025

What this trial tests

trial testing adagrasib (MRTX849) in Advanced Cancer. Approved for marketing.

Quick facts

Lead sponsor	Bristol-Myers Squibb
Status	APPROVED FOR MARKETING
Study type	EXPANDED_ACCESS
Sites	11 locations across United States

Drugs / interventions tested

adagrasib (MRTX849) — full drug profile →

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →
Metastatic Cancer — all drugs for Metastatic Cancer →
Malignant Neoplasm — all drugs for Malignant Neoplasm →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with Advanced Cancer or Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar ME, Kim HJ, Kim DR. · · 2023 · cited 519× · PMID 38105263 · DOI 10.1038/s41392-023-01705-z
The current state of the art and future trends in RAS-targeted cancer therapies.
Punekar SR, Velcheti V, Neel BG, Wong KK. · · 2022 · cited 382× · PMID 36028717 · DOI 10.1038/s41571-022-00671-9
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).
Ou SI, Jänne PA, Leal TA, Rybkin II, et al · · 2022 · cited 240× · PMID 35167329 · DOI 10.1200/jco.21.02752
KRAS: A Druggable Target in Colon Cancer Patients.
Negri F, Bottarelli L, de'Angelis GL, Gnetti L. · · 2022 · cited 36× · PMID 35456940 · DOI 10.3390/ijms23084120
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer.
Lu Y, Yang Y, Zhu G, Zeng H, et al · · 2023 · cited 24× · PMID 37496997 · DOI 10.7150/ijbs.83026
Direct GDP-KRASG12C inhibitors and mechanisms of resistance: the tip of the iceberg.
Rosen JC, Sacher A, Tsao MS. · · 2023 · cited 15× · PMID 36950276 · DOI 10.1177/17588359231160141
Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C, Artru P, Assenat E, Edeline J, et al · · 2023 · cited 9× · PMID 36745342 · DOI 10.1007/s11523-022-00942-6
A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib.
Brazel D, Arter Z, Nagasaka M. · · 2022 · cited 9× · PMID 36387582 · DOI 10.2147/lctt.s383662

Verify or expand the search:

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05162443 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 26 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05162443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing